Business

Announcement on Voluntary Disclosure of Acceptance of the Marketing Authorization Application for the Class 2 Modified New Drug -Morphine Sulfate and Naltrexone Hydrochloride Sustained-release Capsules

Announcement on Voluntary Disclosure of Acceptance of the Marketing Authorization Application for the Class 2 Modified New Drug -Morphine Sulfate and Naltrexone Hydrochloride Sustained-release Capsules

articleChengdu Easton Biopharmaceuticals Co., Ltd. Class AMay 15, 20265/news/announcement-on-voluntary-disclosure-of-acceptance-of-the-marketing-authorization-application-for-the-class-2-modified-new-drug-morphine-sulfate-and-naltrexone-hydrochloride-sustained-release-capsules
Announcement on Voluntary Disclosure of Acceptance of the Marketing Authorization Application for the Class 2 Modified New Drug -Morphine Sulfate and Naltrexone Hydrochloride Sustained-release Capsules

About this update from Chengdu Easton Biopharmaceuticals Co., Ltd. Class A

Announcement on Voluntary Disclosure of Acceptance of the Marketing Authorization Application for the Class 2 Modified New Drug -Morphine Sulfate and Naltrexone Hydrochloride Sustained-release Capsules The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Chengdu Easton Biopharmaceuticals Co., Ltd. Class A